{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:16:28Z","timestamp":1790864188705,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jaci.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T08:57:39Z","timestamp":1731488259000},"page":"31-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Omalizumab safety concerns"],"prefix":"10.1016","volume":"155","author":[{"given":"Thanai","family":"Pongdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2024.11.005_bib1","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","article-title":"Humanization of an antibody directed against IgE","volume":"151","author":"Presta","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A\u00a0systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.11.005_bib4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib5","article-title":"Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials","volume":"11","author":"Wu","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaci.2024.11.005_bib6","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.005_bib8","article-title":"Efficacy and safety of omalizumab for the treatment of severe or poorly controlled allergic diseases in children: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2024.11.005_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib10","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib11","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","article-title":"Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy","volume":"28","author":"Price","year":"2007","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2024.11.005_bib13","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jaip.2020.11.066","article-title":"Successful administration of omalizumab by desensitization protocol following systemic reactions in 12 patients","volume":"9","author":"Bernaola","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.005_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1219735","article-title":"Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management","volume":"4","author":"Sitek","year":"2023","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaci.2024.11.005_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.anai.2021.06.017","article-title":"Use of omalizumab for management of idiopathic anaphylaxis: a systematic review and retrospective case series","volume":"127","author":"Kaminsky","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib17","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/all.13119","article-title":"AllergoOncology - the impact of allergy in oncology: EAACI position paper","volume":"72","author":"Jensen-Jarolim","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2024.11.005_bib19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib21","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib22","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.jaci.2016.12.953","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials","volume":"139","author":"Iribarren","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2024.11.005_bib23","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaip.2024.02.004","article-title":"Systemic inflammation in asthma: what are the risks and impacts outside the airway?","volume":"12","author":"Tattersall","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2024.11.005_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/cvr\/cvae066","article-title":"Mast cells: a novel therapeutic avenue for cardiovascular diseases?","volume":"120","author":"Poto","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaci.2024.11.005_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-016-0565-1","article-title":"IgE and mast cells in host defense against parasites and venoms","volume":"38","author":"Mukai","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2024.11.005_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2222.2007.02650.x","article-title":"Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection","volume":"37","author":"Cruz","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2024.11.005_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100741","article-title":"Omalizumab may protect allergic patients against COVID-19: a systematic review","volume":"16","author":"Ghiglioni","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2024.11.005_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.892277","article-title":"Effectiveness and durability of mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy","volume":"13","author":"Podrazil","year":"2022","journal-title":"Front Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674924011837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:45:28Z","timestamp":1762231528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674924011837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0091674924011837"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2024.11.005","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab safety concerns","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}